^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Ganglioglioma
    Drug:Mekinist (trametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Adjuvant Treatment...Useful in Certain Circumstance...Pilocytic astrocytoma, PXA, ganglioglioma if BRAF V600E activating mutation…trametinib
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.